Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Rheumatoid Arthritis

Free Subscription Articles published in Arthritis Res Ther Retrieve available abstracts of 173 articles: HTML format

Single Articles

March 2023
1. DE MOEL EC, Trouw LA, Terao C, Govind N, et al
   Geo-epidemiology of autoantibodies in rheumatoid arthritis: comparison between four ethnically diverse populations.
   Arthritis Res Ther. 2023;25:37.
   PubMed     Abstract available
   
   
   
2. LIU B, Wang J, Li YY, Li KP, et al
   The association between systemic immune-inflammation index and rheumatoid arthritis: evidence from NHANES 1999-2018.
   Arthritis Res Ther. 2023;25:34.
   PubMed     Abstract available
   
   
   
3. MEHTA B, Goodman S, DiCarlo E, Jannat-Khah D, et al
   Machine learning identification of thresholds to discriminate osteoarthritis and rheumatoid arthritis synovial inflammation.
   Arthritis Res Ther. 2023;25:31.
   PubMed     Abstract available
   
   
   
4. KOH JH, Lee EH, Cha KH, Pan CH, et al
   Factors associated with the composition of the gut microbiome in patients with established rheumatoid arthritis and its value for predicting treatment responses.
   Arthritis Res Ther. 2023;25:32.
   PubMed     Abstract available
   
   
   February 2023
5. EBERHARD A, Rydell E, Forslind K, Bergman S, et al
   Radiographic damage in early rheumatoid arthritis is associated with increased disability but not with pain-a 5-year follow-up study.
   Arthritis Res Ther. 2023;25:29.
   PubMed     Abstract available
   
   
   
6. UMEMOTO A, Kuwada T, Murata K, Shiokawa M, et al
   Identification of anti-citrullinated osteopontin antibodies and increased inflammatory response by enhancement of osteopontin binding to fibroblast-like synoviocytes in rheumatoid arthritis.
   Arthritis Res Ther. 2023;25:25.
   PubMed     Abstract available
   
   
   
7. KENNEY HM, Wood RW, Ramirez G, Bell RD, et al
   Implementation of automated behavior metrics to evaluate voluntary wheel running effects on inflammatory-erosive arthritis and interstitial lung disease in TNF-Tg mice.
   Arthritis Res Ther. 2023;25:17.
   PubMed     Abstract available
   
   
   December 2022
8. DELPLANQUE M, Mekinian A, Georgin-Lavialle S
   Response letter to "Latent class analysis of 216 patients with adult-onset Still's disease" by Sugiyama et al.
   Arthritis Res Ther. 2022;24:285.
   PubMed     Abstract available
   
   
   
9. JIANG YP, Wang S, Lai WD, Wu XQ, et al
   Neuronal CRMP2 phosphorylation inhibition by the flavonoid, naringenin, contributes to the reversal of spinal sensitization and arthritic pain improvement.
   Arthritis Res Ther. 2022;24:277.
   PubMed     Abstract available
   
   
   
10. BIZZARO N, Villalta D, Bini V, Migliorini P, et al
    Multiparametric autoantibody analysis: a new paradigm for the diagnosis of connective tissue diseases.
    Arthritis Res Ther. 2022;24:278.
    PubMed     Abstract available
    
    
    
11. PADULA AS, Pappas DA, Fiore S, Blachley TS, et al
    The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry.
    Arthritis Res Ther. 2022;24:276.
    PubMed     Abstract available
    
    
    
12. YUAN S, Chen J, Ruan X, Vithayathil M, et al
    Rheumatoid arthritis and risk of site-specific cancers: Mendelian randomization study in European and East Asian populations.
    Arthritis Res Ther. 2022;24:270.
    PubMed     Abstract available
    
    
    
13. BIRD A, Oakden-Rayner L, McMaster C, Smith LA, et al
    Artificial intelligence and the future of radiographic scoring in rheumatoid arthritis: a viewpoint.
    Arthritis Res Ther. 2022;24:268.
    PubMed     Abstract available
    
    
    
14. IWAMOTO N, Chiba K, Sato S, Shiraishi K, et al
    Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDM
    Arthritis Res Ther. 2022;24:264.
    PubMed     Abstract available
    
    
    
15. ZHANG Q, Lv X, Wang Y, Wang B, et al
    Expression of CFTR, a hallmark gene of ionocytes, is downregulated in salivary glands of Sjogren's syndrome patients.
    Arthritis Res Ther. 2022;24:263.
    PubMed     Abstract available
    
    
    November 2022
16. LI Q, Li Y, Liang B, Xu R, et al
    Rheumatoid arthritis sera antibodies to citrullinated collagen type II bind to joint cartilage.
    Arthritis Res Ther. 2022;24:257.
    PubMed     Abstract available
    
    
    
17. PARANTAINEN J, Barreto G, Koivuniemi R, Kautiainen H, et al
    The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:256.
    PubMed     Abstract available
    
    
    
18. LI X, Cesta A, Movahedi M, Bombardier C, et al
    Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative.
    Arthritis Res Ther. 2022;24:255.
    PubMed     Abstract available
    
    
    
19. PARK JS, Yang SC, Jeong HY, Lee SY, et al
    EC-18 prevents autoimmune arthritis by suppressing inflammatory cytokines and osteoclastogenesis.
    Arthritis Res Ther. 2022;24:254.
    PubMed     Abstract available
    
    
    
20. BERGMAN M, Tundia N, Martin N, Suboticki JL, et al
    Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Arthritis Res Ther. 2022;24:248.
    PubMed    
    
    
    
21. YAO Y, Cai X, Zhang M, Zhang X, et al
    PSTPIP2 regulates synovial macrophages polarization and dynamics via ERbeta in the joint microenvironment.
    Arthritis Res Ther. 2022;24:247.
    PubMed     Abstract available
    
    
    
22. HEIN TR, Peterson L, Bartikoski BJ, Portes J, et al
    Response to Comment on "The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis".
    Arthritis Res Ther. 2022;24:246.
    PubMed    
    
    
    
23. MINAMINO H, Torii M, Katsushima M, Fujita Y, et al
    Comment on "The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis".
    Arthritis Res Ther. 2022;24:245.
    PubMed     Abstract available
    
    
    October 2022
24. ZHU J, Niu Z, Alfredsson L, Klareskog L, et al
    Response to Comment "Sex-specific exposures and sex-combined outcomes in two-sample Mendelian randomization may mislead the causal inference" on "Age at menarche, age at natural menopause, and risk of rheumatoid arthritis-a Mendelian randomization stu
    Arthritis Res Ther. 2022;24:239.
    PubMed    
    
    
    
25. CHOI B, Park HJ, Song YK, Oh YJ, et al
    Correction: The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study.
    Arthritis Res Ther. 2022;24:238.
    PubMed    
    
    
    
26. WANG Z, Lu J
    Sex-specific exposures and sex-combined outcomes in two-sample Mendelian randomization may mislead the causal inference.
    Arthritis Res Ther. 2022;24:237.
    PubMed     Abstract available
    
    
    
27. CAFARO G, Petito E, Bistoni O, Falcinelli E, et al
    Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment.
    Arthritis Res Ther. 2022;24:236.
    PubMed     Abstract available
    
    
    
28. LU Y, Hao C, Yu S, Ma Z, et al
    Cationic amino acid transporter-1 (CAT-1) promotes fibroblast-like synoviocyte proliferation and cytokine secretion by taking up L-arginine in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:234.
    PubMed     Abstract available
    
    
    
29. KOO BS, Eun S, Shin K, Hong S, et al
    Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:233.
    PubMed     Abstract available
    
    
    
30. KROOS S, Kampstra ASB, Toes REM, Slot LM, et al
    Absence of Epstein-Barr virus DNA in anti-citrullinated protein antibody-expressing B cells of patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:230.
    PubMed     Abstract available
    
    
    
31. MIYAMA K, Bise R, Ikemura S, Kai K, et al
    Deep learning-based automatic-bone-destruction-evaluation system using contextual information from other joints.
    Arthritis Res Ther. 2022;24:227.
    PubMed     Abstract available
    
    
    September 2022
32. KAWABE A, Yamagata K, Kato S, Nakano K, et al
    Role of DNA dioxygenase Ten-Eleven translocation 3 (TET3) in rheumatoid arthritis progression.
    Arthritis Res Ther. 2022;24:222.
    PubMed     Abstract available
    
    
    
33. IBRAHIM F, Ma M, Scott DL, Scott IC, et al
    Defining the relationship between pain intensity and disease activity in patients with rheumatoid arthritis: a secondary analysis of six studies.
    Arthritis Res Ther. 2022;24:218.
    PubMed     Abstract available
    
    
    
34. NOACK M, Miossec P
    Synoviocytes and skin fibroblasts show opposite effects on IL-23 production and IL-23 receptor expression during cell interactions with immune cells.
    Arthritis Res Ther. 2022;24:220.
    PubMed     Abstract available
    
    
    
35. CHEN N, Fan B, He Z, Yu X, et al
    Identification of HBEGF+ fibroblasts in the remission of rheumatoid arthritis by integrating single-cell RNA sequencing datasets and bulk RNA sequencing datasets.
    Arthritis Res Ther. 2022;24:215.
    PubMed     Abstract available
    
    
    August 2022
36. RUBBERT-ROTH A, Furst DE, Fiore S, Praestgaard A, et al
    Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
    Arthritis Res Ther. 2022;24:207.
    PubMed     Abstract available
    
    
    
37. SENARD T, Flouri I, Vuckovic F, Papadaki G, et al
    Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients.
    Arthritis Res Ther. 2022;24:206.
    PubMed     Abstract available
    
    
    
38. HEDENSTIERNA L, Hedstrom AK, Klareskog L, Di Giuseppe D, et al
    Neither low social support nor low decision latitude at work is associated with disease remission among patients with rheumatoid arthritis: results from the Swedish EIRA study.
    Arthritis Res Ther. 2022;24:203.
    PubMed     Abstract available
    
    
    
39. NAVARRO-MILLAN I, Xie F, Crowson CS, Safford MM, et al
    Comparing cardiovascular risk of patients with rheumatoid arthritis within the Social Security Disability Insurance with those commercially insured.
    Arthritis Res Ther. 2022;24:202.
    PubMed     Abstract available
    
    
    
40. GERNERT M, Schmalzing M, Tony HP, Strunz PP, et al
    Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy.
    Arthritis Res Ther. 2022;24:200.
    PubMed     Abstract available
    
    
    
41. FUKUE R, Okazaki Y, Gono T, Kuwana M, et al
    Abatacept downregulates Fcgamma receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:194.
    PubMed     Abstract available
    
    
    
42. CONTRERAS-YANEZ I, Guaracha-Basanez GA, Cuevas-Montoya M, de Jesus Hernandez-Bautista J, et al
    Early persistence on therapy impacts drug-free remission: a case-control study in a cohort of Hispanic patients with recent-onset rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:193.
    PubMed     Abstract available
    
    
    
43. CHOI B, Park HJ, Song YK, Oh YJ, et al
    The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study.
    Arthritis Res Ther. 2022;24:191.
    PubMed     Abstract available
    
    
    
44. FUKUDA W, Kadoya M, Omoto A, Yanagida T, et al
    Treatment of rheumatoid arthritis and its outcomes in an aging society: a single-center cohort study in Japan from 2011 to 2020.
    Arthritis Res Ther. 2022;24:190.
    PubMed     Abstract available
    
    
    
45. DU Y, Cui R, Tian N, Chen M, et al
    Regulation of type I interferon signature by VGLL3 in the fibroblast-like synoviocytes of rheumatoid arthritis patients via targeting the Hippo pathway.
    Arthritis Res Ther. 2022;24:188.
    PubMed     Abstract available
    
    
    
46. SYSOJEV AO, Frisell T, Delcoigne B, Saevarsdottir S, et al
    Does persistence to methotrexate treatment in early rheumatoid arthritis have a familial component?
    Arthritis Res Ther. 2022;24:185.
    PubMed     Abstract available
    
    
    
47. PODEWSKI AF, Glimm AM, Fischer I, Bruyn GAW, et al
    The MCP2 and the wrist plus two extensor compartments are the most affected and responsive joints/tendons out of the US7 score in patients with rheumatoid arthritis-an observational study.
    Arthritis Res Ther. 2022;24:183.
    PubMed     Abstract available
    
    
    
48. PARK E, Ito K, Iqbal R, Amigues I, et al
    Prospective changes in diastolic function in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:184.
    PubMed     Abstract available
    
    
    July 2022
49. JEONG S, Choi S, Park SM, Kim J, et al
    Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
    Arthritis Res Ther. 2022;24:180.
    PubMed     Abstract available
    
    
    
50. WESTERLIND H, Dukuzimana J, Lu X, Alfredsson L, et al
    Investigation of the association between coffee and risk of RA-results from the Swedish EIRA study.
    Arthritis Res Ther. 2022;24:178.
    PubMed     Abstract available
    
    
    
51. GREMESE E, Tolusso B, Petricca L, Di Mario C, et al
    Correction: Peripheral blood CD4(pos)CD25(pos)FoxP3(pos) cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig.
    Arthritis Res Ther. 2022;24:177.
    PubMed    
    
    
    
52. HEIN TR, Peterson L, Bartikoski BJ, Portes J, et al
    The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis.
    Arthritis Res Ther. 2022;24:171.
    PubMed     Abstract available
    
    
    
53. PENG Y, Wu X, Zhang S, Deng C, et al
    The potential roles of type I interferon activated neutrophils and neutrophil extracellular traps (NETs) in the pathogenesis of primary Sjogren's syndrome.
    Arthritis Res Ther. 2022;24:170.
    PubMed     Abstract available
    
    
    
54. RINCON-AREVALO H, Burbano C, Atehortua L, Rojas M, et al
    Modulation of B cell activation by extracellular vesicles and potential alteration of this pathway in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:169.
    PubMed     Abstract available
    
    
    
55. SCIACCA E, Surace AEA, Alaimo S, Pulvirenti A, et al
    Network analysis of synovial RNA sequencing identifies gene-gene interactions predictive of response in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:166.
    PubMed     Abstract available
    
    
    
56. DUONG SQ, Crowson CS, Athreya A, Atkinson EJ, et al
    Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data.
    Arthritis Res Ther. 2022;24:162.
    PubMed     Abstract available
    
    
    June 2022
57. JUNG SM, Han M, Kim EH, Jung I, et al
    Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013-2018.
    Arthritis Res Ther. 2022;24:157.
    PubMed     Abstract available
    
    
    
58. BERGMAN M, Tundia N, Martin N, Suboticki JL, et al
    Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Arthritis Res Ther. 2022;24:155.
    PubMed     Abstract available
    
    
    
59. DAKKAK YJ, van Dijk BT, Jansen FP, Wisse LJ, et al
    Evidence for the presence of synovial sheaths surrounding the extensor tendons at the metacarpophalangeal joints: a microscopy study.
    Arthritis Res Ther. 2022;24:154.
    PubMed     Abstract available
    
    
    
60. SAKELLARIOU G, Scire CA, Rumi F, Carrara G, et al
    Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases.
    Arthritis Res Ther. 2022;24:144.
    PubMed     Abstract available
    
    
    
61. ELISA G, Tolusso B, Petricca L, Di Mario C, et al
    Peripheral blood CD4(pos)CD25(pos)FoxP3(pos) cells and inflammatory cytokines as biomarkers of response in rheumatoid arthritis patients treated with CTLA4-Ig.
    Arthritis Res Ther. 2022;24:143.
    PubMed     Abstract available
    
    
    
62. SAKAI R, Tanaka E, Majima M, Harigai M, et al
    Unincreased risk of hospitalized infection under targeted therapies versus methotrexate in elderly patients with rheumatoid arthritis: a retrospective cohort study.
    Arthritis Res Ther. 2022;24:135.
    PubMed     Abstract available
    
    
    
63. ZENG X, Liu J, Liu X, Wu L, et al
    Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study.
    Arthritis Res Ther. 2022;24:136.
    PubMed     Abstract available
    
    
    
64. SHODA J, Tanaka S, Etori K, Hattori K, et al
    Semaphorin 3G exacerbates joint inflammation through the accumulation and proliferation of macrophages in the synovium.
    Arthritis Res Ther. 2022;24:134.
    PubMed     Abstract available
    
    
    
65. SCHMITT C, Brockwell L, Giraudon M, Zucchetto M, et al
    Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.
    Arthritis Res Ther. 2022;24:133.
    PubMed     Abstract available
    
    
    
66. BERTSIAS A, Avgoustidis N, Papalopoulos I, Repa A, et al
    Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study.
    Arthritis Res Ther. 2022;24:132.
    PubMed     Abstract available
    
    
    
67. KASHIWADO Y, Kiyohara C, Kimoto Y, Nagano S, et al
    Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study.
    Arthritis Res Ther. 2022;24:131.
    PubMed     Abstract available
    
    
    May 2022
68. MARTIN-GONZALEZ C, Martin-Folgueras T, Quevedo-Abeledo JC, de Vera-Gonzalez A, et al
    Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:126.
    PubMed     Abstract available
    
    
    
69. KNITZA J, Tascilar K, Vuillerme N, Eimer E, et al
    Accuracy and tolerability of self-sampling of capillary blood for analysis of inflammation and autoantibodies in rheumatoid arthritis patients-results from a randomized controlled trial.
    Arthritis Res Ther. 2022;24:125.
    PubMed     Abstract available
    
    
    
70. SHI L, Wang J, Guo HX, Han XL, et al
    Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren's syndrome-associated interstitial lung disease.
    Arthritis Res Ther. 2022;24:121.
    PubMed     Abstract available
    
    
    
71. HERTRAMPF S, Klotsche J, Schefer Q, Glimm AM, et al
    Monitoring of patients with rheumatoid arthritis by indocyanine green (ICG)-enhanced fluorescence optical imaging treated with anti-TNFalpha therapy.
    Arthritis Res Ther. 2022;24:117.
    PubMed     Abstract available
    
    
    
72. QIN Y, Wang Y, Meng F, Feng M, et al
    Identification of biomarkers by machine learning classifiers to assist diagnose rheumatoid arthritis-associated interstitial lung disease.
    Arthritis Res Ther. 2022;24:115.
    PubMed     Abstract available
    
    
    
73. KEINDL M, Davies R, Bergum B, Brun JG, et al
    Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sjogren's syndrome.
    Arthritis Res Ther. 2022;24:101.
    PubMed     Abstract available
    
    
    
74. SIGAUX J, Mathieu S, Nguyen Y, Sanchez P, et al
    Impact of type and dose of oral polyunsaturated fatty acid supplementation on disease activity in inflammatory rheumatic diseases: a systematic literature review and meta-analysis.
    Arthritis Res Ther. 2022;24:100.
    PubMed     Abstract available
    
    
    April 2022
75. DE ARMAS-RILLO L, Quevedo-Abeledo JC, Hernandez-Hernandez V, de Vera-Gonzalez A, et al
    The angiopoietin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis is disrupted in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:99.
    PubMed     Abstract available
    
    
    
76. KONDO F, Sugihara T, Umezawa N, Hasegawa H, et al
    Associated factors with poor treatment response to initial glucocorticoid therapy in patients with adult-onset Still's disease.
    Arthritis Res Ther. 2022;24:92.
    PubMed     Abstract available
    
    
    
77. SHARMA S, Plant D, Bowes J, Macgregor A, et al
    HLA-DRB1 haplotypes predict cardiovascular mortality in inflammatory polyarthritis independent of CRP and anti-CCP status.
    Arthritis Res Ther. 2022;24:90.
    PubMed     Abstract available
    
    
    
78. BARTLETT SJ, Bingham CO, van Vollenhoven R, Murray C, et al
    The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
    Arthritis Res Ther. 2022;24:83.
    PubMed     Abstract available
    
    
    March 2022
79. SAKURABA K, Omori Y, Kai K, Terada K, et al
    Risk factor analysis of perioperative complications in patients with rheumatoid arthritis undergoing primary cervical spine surgery.
    Arthritis Res Ther. 2022;24:79.
    PubMed     Abstract available
    
    
    
80. JOO YB, Lee KB, Sul B, Lee HS, et al
    Effect of resistance exercise on serum leptin levels in a prospective longitudinal study of women patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:76.
    PubMed     Abstract available
    
    
    
81. VAN DER LEEUW MS, Messelink MA, Tekstra J, Medina O, et al
    Using real-world data to dynamically predict flares during tapering of biological DMARDs in rheumatoid arthritis: development, validation, and potential impact of prediction-aided decisions.
    Arthritis Res Ther. 2022;24:74.
    PubMed     Abstract available
    
    
    
82. HUSNI ME, Deodhar A, Schwartzman S, Chakravarty SD, et al
    Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Arthritis Res Ther. 2022;24:73.
    PubMed     Abstract available
    
    
    
83. VITTECOQ O, Guillou C, Hardouin J, Gerard B, et al
    Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination.
    Arthritis Res Ther. 2022;24:72.
    PubMed     Abstract available
    
    
    
84. KENNEY HM, Wu CL, Loiselle AE, Xing L, et al
    Single-cell transcriptomics of popliteal lymphatic vessels and peripheral veins reveals altered lymphatic muscle and immune cell populations in the TNF-Tg arthritis model.
    Arthritis Res Ther. 2022;24:64.
    PubMed     Abstract available
    
    
    
85. OCHI S, Sonomoto K, Nakayamada S, Tanaka Y, et al
    Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
    Arthritis Res Ther. 2022;24:61.
    PubMed     Abstract available
    
    
    February 2022
86. MILLIER MJ, Fanning NC, Frampton C, Stamp LK, et al
    Plasma interleukin-23 and circulating IL-17A(+)IFNgamma(+) ex-Th17 cells predict opposing outcomes of anti-TNF therapy in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:57.
    PubMed     Abstract available
    
    
    
87. GOUZE H, Aegerter P, Said-Nahal R, Zins M, et al
    Rheumatoid arthritis, as a clinical disease, but not rheumatoid arthritis-associated autoimmunity, is linked to cardiovascular events.
    Arthritis Res Ther. 2022;24:56.
    PubMed     Abstract available
    
    
    
88. SIMONS G, Caplan J, DiSantostefano RL, Veldwijk J, et al
    Systematic review of quantitative preference studies of treatments for rheumatoid arthritis among patients and at-risk populations.
    Arthritis Res Ther. 2022;24:55.
    PubMed     Abstract available
    
    
    
89. FUJIWARA T, Kondo M, Yamada H, Haraguchi A, et al
    Factors affecting patient satisfaction related to cost and treatment effectiveness in rheumatoid arthritis: results from the multicenter observational cohort study, FRANK Registry.
    Arthritis Res Ther. 2022;24:53.
    PubMed     Abstract available
    
    
    
90. AHMAD HA, Baker JF, Conaghan PG, Emery P, et al
    Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.
    Arthritis Res Ther. 2022;24:47.
    PubMed     Abstract available
    
    
    
91. SORENSEN AS, Andersen MN, Juul-Madsen K, Brokso AD, et al
    Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis.
    Arthritis Res Ther. 2022;24:43.
    PubMed     Abstract available
    
    
    
92. FIECHTER RH, Bolt JW, van de Sande MGH, Aalbers CJ, et al
    Ultrasound-guided lymph node biopsy sampling to study the immunopathogenesis of rheumatoid arthritis: a well-tolerated valuable research tool.
    Arthritis Res Ther. 2022;24:36.
    PubMed     Abstract available
    
    
    January 2022
93. WU YY, Li XF, Wu S, Niu XN, et al
    Role of the S100 protein family in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:35.
    PubMed     Abstract available
    
    
    
94. REBIC N, Munro S, Garg R, Hazlewood G, et al
    "The medications are the decision-makers..." Making reproductive and medication use decisions among female patients with rheumatoid arthritis: a constructivist grounded theory.
    Arthritis Res Ther. 2022;24:31.
    PubMed     Abstract available
    
    
    
95. GARCIA-MONTOYA L, Nam JL, Duquenne L, Villota-Eraso C, et al
    Prioritising referrals of individuals at-risk of RA: guidance based on results of a 10-year national primary care observational study.
    Arthritis Res Ther. 2022;24:26.
    PubMed     Abstract available
    
    
    
96. DE FRANCA NR, Menard HA, Lora M, Zhou Z, et al
    Characterization and use of the ECV304 autoantigenic citrullinome to understand anti-citrullinated protein/peptide autoantibodies in rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:23.
    PubMed     Abstract available
    
    
    
97. BROUWERS H, von Hegedus JH, van der Linden E, Mahdad R, et al
    Hyaluronidase treatment of synovial fluid is required for accurate detection of inflammatory cells and soluble mediators.
    Arthritis Res Ther. 2022;24:18.
    PubMed     Abstract available
    
    
    
98. VERSTAPPEN M, van Steenbergen HW, de Jong PHP, van der Helm-van Mil AHM, et al
    Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution.
    Arthritis Res Ther. 2022;24:4.
    PubMed     Abstract available
    
    
    
99. MEEHAN M, Shah A, Lobo J, Oates J, et al
    Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2022;24:2.
    PubMed     Abstract available
    
    
    
100. BINGHAM CO 3RD, Walker D, Nash P, Lee SJ, et al
     The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
     Arthritis Res Ther. 2022;24:11.
     PubMed     Abstract available
     
     
     
101. SUGIYAMA T, Furuta S, Hiraguri M, Ikeda K, et al
     Latent class analysis of 216 patients with adult-onset Still's disease.
     Arthritis Res Ther. 2022;24:7.
     PubMed     Abstract available
     
     
     December 2021
102. CUTOLO M, Soldano S, Gotelli E, Montagna P, et al
     CTLA4-Ig treatment induces M1-M2 shift in cultured monocyte-derived macrophages from healthy subjects and rheumatoid arthritis patients.
     Arthritis Res Ther. 2021;23:306.
     PubMed     Abstract available
     
     
     
103. ZHANG X, Feng R, Zhao J, Wang Y, et al
     Salivary gland ultrasonography in primary Sjogren's syndrome from diagnosis to clinical stratification: a multicentre study.
     Arthritis Res Ther. 2021;23:305.
     PubMed     Abstract available
     
     
     
104. MOLINA COLLADA J, Lopez Gloria K, Castrejon I, Nieto-Gonzalez JC, et al
     Ultrasound in clinically suspect arthralgia: the role of power Doppler to predict rheumatoid arthritis development.
     Arthritis Res Ther. 2021;23:299.
     PubMed     Abstract available
     
     
     
105. LI R, Liu X, Chen G, Tang G, et al
     Clinical phenotypes and prognostic factors of adult-onset Still's disease: data from a large inpatient cohort.
     Arthritis Res Ther. 2021;23:300.
     PubMed     Abstract available
     
     
     November 2021
106. GEROSSIER E, Nayar S, Froidevaux S, Smith CG, et al
     Cenerimod, a selective S1P1 receptor modulator, improves organ-specific disease outcomes in animal models of Sjogren's syndrome.
     Arthritis Res Ther. 2021;23:289.
     PubMed     Abstract available
     
     
     
107. DOUMEN M, De Cock D, Pazmino S, Bertrand D, et al
     Correction to: Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:285.
     PubMed    
     
     
     
108. REISER C, Klotsche J, Hospach A, Berendes R, et al
     First-year follow-up of children with chronic nonbacterial osteomyelitis-an analysis of the German National Pediatric Rheumatologic Database from 2009 to 2018.
     Arthritis Res Ther. 2021;23:281.
     PubMed     Abstract available
     
     
     
109. LEE SY, Ibrahim F, Tom BDM, Nikiphorou E, et al
     Baseline predictors of remission, pain and fatigue in rheumatoid arthritis: the TITRATE trial.
     Arthritis Res Ther. 2021;23:278.
     PubMed     Abstract available
     
     
     October 2021
110. KOPPEJAN H, Hameetman M, Beyrend G, van Unen V, et al
     Immunoprofiling of early, untreated rheumatoid arthritis using mass cytometry reveals an activated basophil subset inversely linked to ACPA status.
     Arthritis Res Ther. 2021;23:272.
     PubMed     Abstract available
     
     
     
111. MATSUSHITA T, Otani K, Oto Y, Takahashi Y, et al
     Sustained microglial activation in the area postrema of collagen-induced arthritis mice.
     Arthritis Res Ther. 2021;23:273.
     PubMed     Abstract available
     
     
     
112. MICHAEL D, Diederik C, Sofia P, Delphine B, et al
     Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:269.
     PubMed     Abstract available
     
     
     
113. LECHTENBOEHMER CA, Burkard T, Reichenbach S, Walker UA, et al
     Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:267.
     PubMed     Abstract available
     
     
     
114. YIN G, Yang C, Wu G, Yu X, et al
     The protein-protein interaction between connective tissue growth factor and annexin A2 is relevant to pannus formation in rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:266.
     PubMed     Abstract available
     
     
     
115. TSEN SD, Springer LE, Sharmah Gautam K, Tang R, et al
     Non-invasive monitoring of arthritis treatment response via targeting of tyrosine-phosphorylated annexin A2 in chondrocytes.
     Arthritis Res Ther. 2021;23:265.
     PubMed     Abstract available
     
     
     
116. COSTELLO RE, Humphreys JH, Sergeant JC, Haris M, et al
     Correction to: Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the Preclinical EValuation of Novel Targ
     Arthritis Res Ther. 2021;23:263.
     PubMed    
     
     
     
117. GAN Y, Sun Y, Jin J, Wang Y, et al
     bFGF could be a biomarker of malignancy in RS3PE syndrome: an ambispective single-center cohort analysis of 51 patients.
     Arthritis Res Ther. 2021;23:261.
     PubMed     Abstract available
     
     
     
118. HAN S, Kim NR, Kang JW, Eun JS, et al
     Radial BMD and serum CTX-I can predict the progression of carotid plaque in rheumatoid arthritis: a 3-year prospective cohort study.
     Arthritis Res Ther. 2021;23:258.
     PubMed     Abstract available
     
     
     
119. WANG Q, Che N, Lu C, Sun X, et al
     Correlation of peripheral CD4+GranzB+CTLs with disease severity in patients with primary Sjogren's syndrome.
     Arthritis Res Ther. 2021;23:257.
     PubMed     Abstract available
     
     
     
120. WAHBI A, Tessoulin B, Bretonniere C, Boileau J, et al
     Catastrophic adult-onset Still's disease as a distinct life-threatening clinical subset: case-control study with dimension reduction analysis.
     Arthritis Res Ther. 2021;23:256.
     PubMed     Abstract available
     
     
     
121. LEE S, Kang S, Eun Y, Won HH, et al
     Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis.
     Arthritis Res Ther. 2021;23:254.
     PubMed     Abstract available
     
     
     September 2021
122. XU X, Geng L, Chen C, Kong W, et al
     Olfactory impairment in patients with primary Sjogren's syndrome and its correlation with organ involvement and immunological abnormalities.
     Arthritis Res Ther. 2021;23:250.
     PubMed     Abstract available
     
     
     
123. FLEISCHMANN RM, Alvarez DF, Bock AE, Cronenberger C, et al
     Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira(R)) or continuing biosimilar therapy: week 52-92 data from a randomized,
     Arthritis Res Ther. 2021;23:248.
     PubMed     Abstract available
     
     
     
124. KIM GH, Park YJ
     Accelerated diastolic dysfunction in premenopausal women with rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:247.
     PubMed     Abstract available
     
     
     
125. PETERSON MN, Dykhoff HJ, Crowson CS, Davis JM 3rd, et al
     Risk of rheumatoid arthritis diagnosis in statin users in a large nationwide US study.
     Arthritis Res Ther. 2021;23:244.
     PubMed     Abstract available
     
     
     
126. RIGBY W, Buckner JH, Louis Bridges S Jr, Nys M, et al
     HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.
     Arthritis Res Ther. 2021;23:245.
     PubMed     Abstract available
     
     
     
127. HAN Y, Wang J, Li S, Li Y, et al
     Isopsoralen ameliorates rheumatoid arthritis by targeting MIF.
     Arthritis Res Ther. 2021;23:243.
     PubMed     Abstract available
     
     
     
128. MARKLEIN B, Jenning M, Konthur Z, Haupl T, et al
     The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success" in RA patients.
     Arthritis Res Ther. 2021;23:239.
     PubMed     Abstract available
     
     
     
129. MEASE PJ, Stryker S, Liu M, Salim B, et al
     Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry.
     Arthritis Res Ther. 2021;23:236.
     PubMed     Abstract available
     
     
     
130. REIJM S, Kissel T, Stoeken-Rijsbergen G, Slot LM, et al
     Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load.
     Arthritis Res Ther. 2021;23:230.
     PubMed     Abstract available
     
     
     August 2021
131. HIROSE W, Harigai M, Amano K, Hidaka T, et al
     Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:228.
     PubMed     Abstract available
     
     
     
132. TANAKA Y, Takeuchi T, Izutsu H, Kaneko Y, et al
     Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:221.
     PubMed     Abstract available
     
     
     
133. WANG Y, Chen S, Zheng S, Lin J, et al
     The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical applica
     Arthritis Res Ther. 2021;23:212.
     PubMed     Abstract available
     
     
     
134. COSTELLO RE, Humphreys JH, Sergeant JC, Haris M, et al
     Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PRE
     Arthritis Res Ther. 2021;23:210.
     PubMed     Abstract available
     
     
     
135. WESTERLIND H, Palmqvist I, Saevarsdottir S, Alfredsson L, et al
     Is tea consumption associated with reduction of risk of rheumatoid arthritis? A Swedish case-control study.
     Arthritis Res Ther. 2021;23:209.
     PubMed     Abstract available
     
     
     
136. TRANG DAMT, Okamura K, Suto T, Sakane H, et al
     Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
     Arthritis Res Ther. 2021;23:206.
     PubMed     Abstract available
     
     
     July 2021
137. AJEGANOVA S, Andersson MLE, Frostegard J, Hafstrom I, et al
     Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events.
     Arthritis Res Ther. 2021;23:201.
     PubMed     Abstract available
     
     
     
138. IWAMOTO N, Sato S, Kurushima S, Michitsuji T, et al
     Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:197.
     PubMed     Abstract available
     
     
     
139. MINAMINO H, Katsushima M, Fujita Y, Hashimoto M, et al
     Comment on "Urinary sodium-to-potassium ratio associates with hypertension and current disease activity in patients with rheumatoid arthritis: a cross-sectional study": authors' reply.
     Arthritis Res Ther. 2021;23:195.
     PubMed    
     
     
     
140. STOCKFELT M, Lundell AC, Hetland ML, Ostergaard M, et al
     Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.
     Arthritis Res Ther. 2021;23:189.
     PubMed     Abstract available
     
     
     
141. ANDONIAN BJ, Johannemann A, Hubal MJ, Pober DM, et al
     Altered skeletal muscle metabolic pathways, age, systemic inflammation, and low cardiorespiratory fitness associate with improvements in disease activity following high-intensity interval training in persons with rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:187.
     PubMed     Abstract available
     
     
     
142. MESSELINK MA, Roodenrijs NMT, van Es B, Hulsbergen-Veelken CAR, et al
     Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon.
     Arthritis Res Ther. 2021;23:184.
     PubMed     Abstract available
     
     
     
143. JUNG SY, Koh JH, Kim KJ, Park YW, et al
     Switching from TNFalpha inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFalpha inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial.
     Arthritis Res Ther. 2021;23:182.
     PubMed     Abstract available
     
     
     
144. CORRADO A, Rotondo C, Mele A, Cici D, et al
     Influence of glucocorticoid treatment on trabecular bone score and bone remodeling regulators in early rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:180.
     PubMed     Abstract available
     
     
     
145. KOO BS, Eun S, Shin K, Yoon H, et al
     Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics.
     Arthritis Res Ther. 2021;23:178.
     PubMed     Abstract available
     
     
     
146. PARK JK, Shon S, Yoo HJ, Suh DH, et al
     Inhibition of histone deacetylase 6 suppresses inflammatory responses and invasiveness of fibroblast-like-synoviocytes in inflammatory arthritis.
     Arthritis Res Ther. 2021;23:177.
     PubMed     Abstract available
     
     
     
147. CHO SK, Kim H, Lee J, Nam E, et al
     Effectiveness of bazedoxifene in preventing glucocorticoid-induced bone loss in rheumatoid arthritis patients.
     Arthritis Res Ther. 2021;23:176.
     PubMed     Abstract available
     
     
     June 2021
148. MAARSEVEEN TD, Maurits MP, Niemantsverdriet E, van der Helm-van Mil AHM, et al
     Handwork vs machine: a comparison of rheumatoid arthritis patient populations as identified from EHR free-text by diagnosis extraction through machine-learning or traditional criteria-based chart review.
     Arthritis Res Ther. 2021;23:174.
     PubMed     Abstract available
     
     
     
149. EBERHARD A, Bergman S, Mandl T, Olofsson T, et al
     Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis-an inception cohort study.
     Arthritis Res Ther. 2021;23:169.
     PubMed     Abstract available
     
     
     
150. HUR B, Gupta VK, Huang H, Wright KA, et al
     Plasma metabolomic profiling in patients with rheumatoid arthritis identifies biochemical features predictive of quantitative disease activity.
     Arthritis Res Ther. 2021;23:164.
     PubMed     Abstract available
     
     
     
151. DEMORUELLE MK, Wang H, Davis RL, Visser A, et al
     Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:163.
     PubMed     Abstract available
     
     
     
152. FERRAZ-AMARO I, Corrales A, Quevedo-Abeledo JC, Vegas-Revenga N, et al
     Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk.
     Arthritis Res Ther. 2021;23:162.
     PubMed     Abstract available
     
     
     
153. GIOLLO A, Cioffi G, Ognibeni F, Orsolini G, et al
     Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:158.
     PubMed     Abstract available
     
     
     
154. MIYAZAKI Y, Nakano K, Nakayamada S, Kubo S, et al
     Serum TNFalpha levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study.
     Arthritis Res Ther. 2021;23:154.
     PubMed     Abstract available
     
     
     May 2021
155. RICHTER JG, Chehab G, Schwartz C, Ricken E, et al
     The PICASO cloud platform for improved holistic care in rheumatoid arthritis treatment-experiences of patients and clinicians.
     Arthritis Res Ther. 2021;23:151.
     PubMed     Abstract available
     
     
     
156. MATSUMOTO H, Fujita Y, Matsuoka N, Temmoku J, et al
     Serum checkpoint molecules in patients with IgG4-related disease (IgG4-RD).
     Arthritis Res Ther. 2021;23:148.
     PubMed     Abstract available
     
     
     
157. OLIVER J, Nair N, Orozco G, Smith S, et al
     Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment.
     Arthritis Res Ther. 2021;23:139.
     PubMed    
     
     
     April 2021
158. JIN S, Li M, Wang Q, Zeng X, et al
     Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT.
     Arthritis Res Ther. 2021;23:127.
     PubMed     Abstract available
     
     
     
159. SEGU-VERGES C, Coma M, Kessel C, Smeets S, et al
     Application of systems biology-based in silico tools to optimize treatment strategy identification in Still's disease.
     Arthritis Res Ther. 2021;23:126.
     PubMed     Abstract available
     
     
     
160. KIM KW, Kim BM, Won JY, Min HK, et al
     Regulation of osteoclastogenesis by mast cell in rheumatoid arthritis.
     Arthritis Res Ther. 2021;23:124.
     PubMed     Abstract available
     
     
     
161. COMBE B, Allanore Y, Alten R, Caporali R, et al
     Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.
     Arthritis Res Ther. 2021;23:119.
     PubMed     Abstract available
     
     
     
162. JINNO S, Onishi A, Dubreuil M, Hashimoto M, et al
     Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
     Arthritis Res Ther. 2021;23:116.
     PubMed     Abstract available
     
     
     
163. ZHU J, Niu Z, Alfredsson L, Klareskog L, et al
     Age at menarche, age at natural menopause, and risk of rheumatoid arthritis - a Mendelian randomization study.
     Arthritis Res Ther. 2021;23:108.
     PubMed     Abstract available
     
     
     
164. MATSUMOTO Y, Shivappa N, Sugioka Y, Tada M, et al
     Change in dietary inflammatory index score is associated with control of long-term rheumatoid arthritis disease activity in a Japanese cohort: the TOMORROW study.
     Arthritis Res Ther. 2021;23:105.
     PubMed     Abstract available
     
     
     
165. AKGUL A, Maddaloni M, Jun SM, Nelson AS, et al
     Stimulation of regulatory T cells with Lactococcus lactis expressing enterotoxigenic E. coli colonization factor antigen 1 retains salivary flow in a genetic model of Sjogren's syndrome.
     Arthritis Res Ther. 2021;23:99.
     PubMed     Abstract available
     
     
     March 2021
166. WAN L, Gao Y, Gu J, Chi H, et al
     Total metabolic lesion volume of lymph nodes measured by (18)F-FDG PET/CT: a new predictor of macrophage activation syndrome in adult-onset Still's disease.
     Arthritis Res Ther. 2021;23:97.
     PubMed     Abstract available
     
     
     February 2021
167. LIU M, Xie Z, Sun G, Chen L, et al
     Macrophage migration inhibitory factor may play a protective role in osteoarthritis.
     Arthritis Res Ther. 2021;23:59.
     PubMed     Abstract available
     
     
     
168. NOWELL WB, Gavigan K, Kannowski CL, Cai Z, et al
     Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower.
     Arthritis Res Ther. 2021;23:53.
     PubMed     Abstract available
     
     
     January 2021
169. HEMSHEKHAR M, Anaparti V, El-Gabalawy H, Mookherjee N, et al
     A bioavailable form of curcumin, in combination with vitamin-D- and omega-3-enriched diet, modifies disease onset and outcomes in a murine model of collagen-induced arthritis.
     Arthritis Res Ther. 2021;23:39.
     PubMed     Abstract available
     
     
     
170. SOLOMON DH, Xu C, Collins J, Kim SC, et al
     The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy.
     Arthritis Res Ther. 2021;23:26.
     PubMed     Abstract available
     
     
     
171. MURRAY K, Turk M, Alammari Y, Young F, et al
     Long-term remission and biologic persistence rates: 12-year real-world data.
     Arthritis Res Ther. 2021;23:25.
     PubMed     Abstract available
     
     
     April 2020
172. TUNCEL J, Holmberg J, Haag S, Hopkins MH, et al
     Self-reactive T cells induce and perpetuate chronic relapsing arthritis.
     Arthritis Res Ther. 2020;22:95.
     PubMed     Abstract available
     
     
     
173. YATES M, Bechman K, Dennison EM, MacGregor AJ, et al
     Data quality predicts care quality: findings from a national clinical audit.
     Arthritis Res Ther. 2020;22:87.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Rheumatoid Arthritis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: